WO2005032481A2 - Quinazoline derivatives as medicaments - Google Patents

Quinazoline derivatives as medicaments Download PDF

Info

Publication number
WO2005032481A2
WO2005032481A2 PCT/US2004/032430 US2004032430W WO2005032481A2 WO 2005032481 A2 WO2005032481 A2 WO 2005032481A2 US 2004032430 W US2004032430 W US 2004032430W WO 2005032481 A2 WO2005032481 A2 WO 2005032481A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
independently
phenyl
compounds
Prior art date
Application number
PCT/US2004/032430
Other languages
English (en)
French (fr)
Other versions
WO2005032481A3 (en
Inventor
Sundeep Dugar
Sarvajit Chakravarty
Alison Murphy
Glen Mcenroe
Aurelia Conte
John J. Perumattam
Original Assignee
Scios Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc. filed Critical Scios Inc.
Publication of WO2005032481A2 publication Critical patent/WO2005032481A2/en
Publication of WO2005032481A3 publication Critical patent/WO2005032481A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
PCT/US2004/032430 2003-09-30 2004-09-30 Quinazoline derivatives as medicaments WO2005032481A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50791003P 2003-09-30 2003-09-30
US60/507,910 2003-09-30

Publications (2)

Publication Number Publication Date
WO2005032481A2 true WO2005032481A2 (en) 2005-04-14
WO2005032481A3 WO2005032481A3 (en) 2005-06-16

Family

ID=34421686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/032430 WO2005032481A2 (en) 2003-09-30 2004-09-30 Quinazoline derivatives as medicaments

Country Status (2)

Country Link
US (2) US7232824B2 (US20050096333A1-20050505-C00026.png)
WO (1) WO2005032481A2 (US20050096333A1-20050505-C00026.png)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040966A1 (ja) * 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
WO2006100310A1 (en) * 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
WO2006105063A1 (en) * 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
WO2006120252A2 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
WO2006120251A1 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pteridines useful as hcv inhibitors and methods for the preparation thereof
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
US7977342B2 (en) 2004-09-30 2011-07-12 Tibotec-Virco Virology Bvba HCV inhibiting bi-cyclic pyrimidines
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8603971B2 (en) 2005-09-16 2013-12-10 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
AU2015340215B2 (en) * 2014-10-29 2018-11-15 Dong-A St Co., Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
CN109265457A (zh) * 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP2019526550A (ja) * 2016-08-15 2019-09-19 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
JP2020504173A (ja) * 2016-12-20 2020-02-06 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11865120B2 (en) 2013-08-23 2024-01-09 Neupharma, Inc. Substituted quinazolines for inhibiting kinase activity

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104225574B (zh) 2003-02-04 2017-01-11 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP2604621B1 (en) 2003-05-01 2015-10-21 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
MXPA06008157A (es) * 2003-12-24 2007-09-07 Johnson & Johnson Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
JP4931604B2 (ja) 2004-01-23 2012-05-16 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
SI2252312T1 (sl) 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
US20100331265A1 (en) 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
EP3318264A1 (en) 2009-08-24 2018-05-09 Stealth Peptides International, Inc. Methods ans compositions for preventing or treating opthalmic conditions
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476031B1 (en) * 1998-08-28 2002-11-05 Scios, Inc. Quinazoline derivatives as medicaments
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
WO2004047818A2 (en) * 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1175875A (en) 1983-02-25 1984-10-09 Office Specialty Division Of Hollanding Inc. Anti-tip blocking device
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
EP0634169B1 (en) 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
JP2001506230A (ja) 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476031B1 (en) * 1998-08-28 2002-11-05 Scios, Inc. Quinazoline derivatives as medicaments
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
WO2004047818A2 (en) * 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977342B2 (en) 2004-09-30 2011-07-12 Tibotec-Virco Virology Bvba HCV inhibiting bi-cyclic pyrimidines
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
WO2006040966A1 (ja) * 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
WO2006100310A1 (en) * 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
WO2006105063A1 (en) * 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
US8030318B2 (en) 2005-03-25 2011-10-04 Tibotec Pharmaceuticals Ltd. Fused bicyclic inhibitors of HCV
WO2006120252A3 (en) * 2005-05-12 2007-02-22 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
US9951075B2 (en) 2005-05-12 2018-04-24 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
CN101203515A (zh) * 2005-05-12 2008-06-18 泰博特克药品有限公司 用作HCV抑制剂的吡啶并[2,3-d]嘧啶类及其制备方法
JP2008540493A (ja) * 2005-05-12 2008-11-20 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｃｖ阻害剤として有用なプテリジンおよびその製造方法
JP2008540494A (ja) * 2005-05-12 2008-11-20 テイボテク・フアーマシユーチカルズ・リミテツド ＨＣＶ阻害剤として有用なピリド［２，３−ｄ］ピリミジンおよびその製造方法
AU2006245676B2 (en) * 2005-05-12 2012-08-02 Janssen Sciences Ireland Uc Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US9708328B2 (en) 2005-05-12 2017-07-18 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
US9290502B2 (en) 2005-05-12 2016-03-22 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
WO2006120252A2 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
WO2006120251A1 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pteridines useful as hcv inhibitors and methods for the preparation thereof
US8022077B2 (en) 2005-05-12 2011-09-20 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US8603971B2 (en) 2005-09-16 2013-12-10 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
CN102552874B (zh) * 2005-09-16 2015-04-22 科内尔研究基金会 用于减少cd36表达的方法
US9150614B2 (en) 2005-09-16 2015-10-06 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US11447523B2 (en) 2005-09-16 2022-09-20 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
JP2009521479A (ja) * 2005-12-21 2009-06-04 アボット・ラボラトリーズ 抗ウイルス化合物
WO2007076034A3 (en) * 2005-12-21 2007-10-04 Abbott Lab Anti-viral compounds
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EP3254696A1 (en) 2006-10-03 2017-12-13 Genzyme Corporation Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EP2918288A1 (en) 2006-10-03 2015-09-16 Genzyme Corporation Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US9925154B2 (en) 2011-10-26 2018-03-27 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US11865120B2 (en) 2013-08-23 2024-01-09 Neupharma, Inc. Substituted quinazolines for inhibiting kinase activity
AU2015340215B2 (en) * 2014-10-29 2018-11-15 Dong-A St Co., Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
JP2022058912A (ja) * 2016-08-15 2022-04-12 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
JP2019526550A (ja) * 2016-08-15 2019-09-19 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
JP2020504173A (ja) * 2016-12-20 2020-02-06 オリゴメリックス インコーポレイテッド タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
US11472776B2 (en) 2016-12-20 2022-10-18 Oligomerix, Inc. Quinazolinones that inhibit the formation of tau oligomers and their method of use
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
CN109265457A (zh) * 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions

Also Published As

Publication number Publication date
US7232824B2 (en) 2007-06-19
US20070293500A1 (en) 2007-12-20
US20050096333A1 (en) 2005-05-05
WO2005032481A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US7232824B2 (en) Quinazoline derivatives as medicaments
EP1107959B1 (en) Quinazoline derivatives as medicaments
AU2006226322B2 (en) Heterobicylic inhibitors of HCV
KR101311757B1 (ko) 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온
AU763839B2 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US20070066632A1 (en) Fused bicyclic inhibitors of TGFbeta
CZ139097A3 (cs) 6-Arylpyrido[2,3-d]pyrimidiny a naftyridiny a farmaceutické prostředky na jejich bázi
JP2006521398A (ja) ＴＧＦβの二−環式ピリミジン阻害剤
KR20080006614A (ko) 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
US20060281763A1 (en) Carboxamide inhibitors of TGFbeta
US20040132730A1 (en) Inhibitors of TGFbeta
JP6916562B2 (ja) 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase